Eric593 you need to read my statement "In real clinical situations". You then give data from clinical trials which are not real clinical situations. I don't know if you misread my comment or are just being provocative and giving the 'group think' view ?
I'm still not clear then. Do you have a reference for your statement that in real clinical situations, the meds work on 1/3 of people?
Work how much? Reduce relapses for 1/3 by how much? So, they don't affect MS AT ALL in the rest?
Because if they reduce relapse rate overall by 30%, and if you're saying they work in only 1/3 of people using them, I'm curious how well they work in that 1/3 if, in the ENTIRE population they only reduce 30% of relapses. If they only work in a 1/3 of the people, then 67% of people are not benefitting... at all? So 33% are benefitting quite a bit and their relapse rates are significantly impacted?
Is that what you're saying? Do you have a study or a link to this? Because this is new information for me and I'd like to understand it more clearly.
I have been digging around and I have been unable to find a study that gives such high numbers. Of course, there are a lot of studies out there and I only have access to the abstracts (if that) since many require a subscription to access them.
I would love to read this research that gives such a great percentage. 30% is pretty high considering most things I have come across have been much less.
Here are some papers I found, none of which give out exact percentages of results, only probability numbers (denoted by the capital italicized P
Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: A comparative cohort study (2007)
Reduced effectiveness of long-term interferon-ß treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study (2007)
Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications (2009)
Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data (2007)
Interferon-β Treatment for Multiple Sclerosis (2007)
Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS (2000)
Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up (2002)
A prospective, open-label treatment trial to compare the effect of IFN β-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis (2008)
HOW EFFECTIVE ARE DISEASE-MODIFYING DRUGS IN DELAYING PROGRESSION IN RELAPSING-ONSET MS (2008)
***NO information is available on this without purchase…quite annoying if you ask me.